| Name |
CAS |
MF |
MW |
Single-letter sequence |
Three-letter sequence |
Number of AA |
Type |
Inquiry |
| CREKA peptide |
847058-45-1 |
C23H43N9O8S1 |
605.71 |
H2N-CREKA-OH |
H2N-Cys-Arg-Glu-Lys-Ala-OH |
5 |
Self-assembling short peptides |
|
| NDI-Lyso |
2999646-19-2 |
C71H100N22O13 |
1469.69 |
{Hexyl-NDI-βAla}-FFRRRRK |
{Hexyl-NDI-βAla}-Phe-Phe-Arg-Arg-Arg-Arg-Lys |
7 |
Lysosome-targeted anticancer agents |
|
| HTTIPKV |
|
C36H62N10O10 |
794.94 |
H2N-HTTIPKV-OH |
H2N-His-Thr-Thr-Ile-Pro-Lys-Val-OH |
7 |
Cancer-associated fibroblast (CAF)–targeting peptide |
|
| CGEMGWVRC |
|
C42H65N13O12S3 |
1040.24 |
H2N-CGEMGWVRC-OH |
H2N-Cys-Gly-Glu-Met-Gly-Trp-Val-Arg-Cys-OH |
9 |
Interleukin-13 receptor α2–targeting peptide |
|
| Prepro-von Willebrand factor (641-650) (bovine) |
143470-36-4 |
C54H78N14O15S1 |
1195.35 |
H2N-WREPSFCALS-OH |
H2N-Trp-Arg-Glu-Pro-Ser-Phe-Cys-Ala-Leu-Ser-OH |
10 |
Type I collagen–targeting peptide |
|
| DSSDSSDSSDSSDSSDSS |
|
C60H92N18O43 |
1753.47 |
H2N-DSSDSSDSSDSSDSSDSS-OH |
H2N-Asp-Ser-Ser-Asp-Ser-Ser-Asp-Ser-Ser-Asp-Ser-Ser-Asp-Ser-Ser-Asp-Ser-Ser-OH |
18 |
Hydroxyapatite-targeting peptide |
|
| LSNNNLR |
|
C33H59N13O12 |
829.9 |
H2N-LSNNNLR-OH |
H2N-Leu-Ser-Asn-Asn-Asn-Leu-Arg-OH |
7 |
PC-3 cell–targeting peptide |
|
| CAHLHNRS |
|
C37H60N16O11S1 |
937.04 |
H2N-CAHLHNRS-OH |
H2N-Cys-Ala-His-Leu-His-Asn-Arg-Ser-OH |
8 |
TfR-targeting peptide |
|
| STFTKSP |
|
C34H54N8O12 |
766.84 |
H2N-STFTKSP-OH |
H2N-Ser-Thr-Phe-Thr-Lys-Ser-Pro-OH |
7 |
Hematopoietic stem cell–targeting peptide |
|
| SNF |
|
C41H58N8O11S1 |
871.01 |
H2N–SNFYMPL–OH |
H2N–Ser–Asn–Phe–Tyr–Met–Pro–Leu–OH |
7 |
Q-hTERT cell–targeting peptide |
|
| SDSSD |
|
C17H27N5O13 |
509.42 |
H2N-SDSSD-OH |
H2N-Ser-Asp-Ser-Ser-Asp-OH |
5 |
Osteoblast-specific factor-2–targeting peptide |
|
| RTDLDSLRTYTL |
222557-93-9 |
C62H104N18O22 |
1453.6 |
H2N-RTDLDSLRTYTL-OH |
H2N-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-Thr-Tyr-Thr-Leu-OH |
12 |
integrin (αvβ6) inhibitor |
|
| Galanin (1-13)-spantide I |
143868-20-6 |
C138H199N35O30 |
2828.27 |
H2N-GWTLNSAGYLLGPRPKPQQWFWLL-NH2 |
H2N-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Arg-Pro-Lys-Pro-Gln-Gln-Trp-Phe-Trp-Leu-Leu-NH2 |
24 |
|
|
| Phage-derived 12/1 peptide |
186180-20-1 |
C71H99N17O19S2 |
1558.78 |
H2N-MPRFMDYWEGLN-OH |
H2N-Met-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-OH |
12 |
|
|
| HSSP |
|
C17H26N6O7 |
426.42 |
H2N-HSSP-OH |
H2N-His-Ser-Ser-Pro-OH |
4 |
HMOX1-targeting peptide |
|
| TD2.2 |
|
C155H253N53O42 |
3528.93 |
H2N-SYWYRIVLSRTGRNGRLRVGRERPVLGESP-OH |
H2N-Ser-Tyr-Trp-Tyr-Arg-Ile-Val-Leu-Ser-Arg-Thr-Gly-Arg-Asn-Gly-Arg-Leu-Arg-Val-Gly-Arg-Glu-Arg-Pro-Val-Leu-Gly-Glu-Ser-Pro-OH |
30 |
Oligodendrocyte-targeting peptide |
|
| LGLLLRHLRHHSNLLANI |
222557-92-8 |
C94H160N32O22 |
2090.48 |
H2N-LGLLLRHLRHHSNLLANI-OH |
H2N-Leu-Gly-Leu-Leu-Leu-Arg-His-Leu-Arg-His-His-Ser-Asn-Leu-Leu-Ala-Asn-Ile-OH |
18 |
|
|
| Protein Kinase C (660-673) |
149839-94-1 |
C74H115N17O23 |
1610.81 |
H2N-SFVNSEFLKPEVKS-OH |
H2N-Ser-Phe-Val-Asn-Ser-Glu-Phe-Leu-Lys-Pro-Glu-Val-Lys-Ser-OH |
14 |
|
|
| CKSTHDRLC |
|
C41H69N15O14S2 |
1060.21 |
H2N-CKSTHDRLC-OH |
H2N-Cys-Lys-Ser-Thr-His-Asp-Arg-Leu-Cys-OH |
9 |
Synovium-targeting peptide |
|
| RP-832c |
|
C68H94N20O11 |
1367.6 |
H2N-RWKFGGFKWR-OH |
H2N-Arg-Trp-Lys-Phe-Gly-Gly-Phe-Lys-Trp-Arg-OH |
10 |
CD206-targeting peptide |
|
